Satya Marar: How Cheap GLP-1s Could Save Lives — AND Kill Pharma Innovation

The era of GLP-1 weight-loss therapies has erupted into a high-stakes showdown: major drugmakers are slashing sticker prices while regulators grapple with mounting safety and access concerns. Just recently, Wegovy and Ozempic manufacturers announced a 30% cash-price reduction for uninsured Americans. Simultaneously, three new independent reviews warn of long-term unknowns and major equity gaps in who actually benefits. With regulators scrambling to assess safety, equity, and access amid skyrocketing demand, Young Voices Contributor Satya Marar brings a crucial, nonpartisan lens from his latest article on how this policy shift reshapes innovation, affordability, and the long-term sustainability of America’s health-care system. He joins Samantha Mandel on WRFH to discuss.